The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 18th - 24th, 2023.
He highlights the TROPiCS-02 trial of sacituzumab govitecan demonstrating significant overall survival improvement over chemotherapy in patients with pretreated endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer.
He also covers the TBCRC 030 trial which looked at circulating tumour DNA analysis as a predictive biomarker in early-stage triple-negative breast cancer.
In addition, he covers the use of stereotactic body radiotherapy as an effective treatment modality for hepatocellular carcinoma patients with mature follow-up.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
Prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
